Insurance coverage remained historically high, though it declined slightly from its peak. In 2024, 91.8% of the population was insured, down from 92.5% in 2023. Private health insurance enrollment ...

SB 41 prohibits spread pricing, requires PBMs and group purchasing organizations to pass through 100% of manufacturer rebates ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

Kristine Rawlings, PharmD | Authors | Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Children’s Hospital of Philadelphia (CHOP) has partnered with Soar Autism Center to expand access to early autism care in the Philadelphia region through a new network of integrated outpatient therapy ...

TikTok videos by physicians on mammograms scored highest in quality, highlighting the importance of professional involvement in health information dissemination. The DISCERN tool was used to evaluate ...

In a study of more than 31,000 adults, an EHR-integrated patient-facing tool significantly improved identification of ...

The study revealed that the strongest and most consistent evidence supports music-based sleep aids. Across multiple studies, listening to calming music before bedtime was linked to better sleep ...

Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen receptor (CAR) T-cell therapy by 2030 through disease awareness and sustainable ...